TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) (“Urbanfund” or the “Company”), confirmed today that the Company has filed its financial statements for the year ended December 31, 2024 (the “Consolidated Financial Statements”) and corresponding Management’s Discussion and Analysis (“MD&A”). BUSINESS OVERVIEW AND STRATEGY Business Overview Urbanfund Corp. is an incorporated entity listed on the TSX Venture Exchange (“TSX-V”) un ...

CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- Canacol Energy Ltd. ("Canacol" or the "Corporation") (TSX:CNE; OTCQX:CNNEF; BVC:CNEC) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, after the market closure. Senior Management will hold a Conference Call to discuss results on Friday, May 9, 2025, at 8:00 a.m. MT / 10:00 a.m. ET. The conference call may be accessed by dial in or via webcast: Pre-register for the Conference Call:https://dpregister.com/sreg/10199336/ff099f3 ...

ROHM's Latest 2kV SiC MOSFETs Featured in Semikron Danfoss' Module for SMA Solar Technology Engineered to support simple highly efficient converter technologies for 1500V DC links. Santa Clara, CA and Kyoto, Japan, April 28, 2025 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced that SMA Solar Technology AG, a leading global specialist in photovoltaic and storage system technology, has adopted Semikron Danfoss’ Module featuring ROHM’s latest 2kV SiC MOSFETs for its new large-scale power conversion ...

Greenville, South Carolina, April 28, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) is pleased to report that it has filed its 2024 year end, audited Financial Statements and related Management Discussion and Analysis as summarized below. The Company also reports the appointment of Adam Ho as interim Chief Financial Officer, effective May 1, 2025. Mr. Ho will succeed Jason Tong, who will continue to serve as the Company’s Controller. Mr. Ho also serves as a Director of ...

MEMPHIS, Tenn., April 28, 2025 (GLOBE NEWSWIRE) -- AutoZone, Inc. (NYSE: AZO), the leading retailer and distributor of automotive replacement parts and accessories in the Americas, will release results for its third quarter ended Saturday, May 10, 2025, before market open on Tuesday, May 27, 2025. Additionally, the Company will host a one-hour conference call on Tuesday, May 27, 2025, beginning at 10:00 a.m. (ET), to discuss the results of the quarter. This call is being webcast and can be accessed, along w ...

VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Finning International Inc. (TSX: FTT) (“Finning”) will report Q1 2025 results on May 12, 2025 after markets close and hold the investor call on May 13, 2025 at 10:00 AM Eastern Time. To access the investor call, please dial 1-833-752-3398 (Canada and US toll free) or 1-647-846-2852 (international toll). The investor call will be webcast live and archived for three months. Please visit our website to access the webcast and accompanying presentat ...

文章核心观点 公司宣布进行非经纪私募配售，拟发售最多16,666,667个单位，筹集最多200万美元，用于资本支出等用途，预计在5月9日前完成 [1][3][4] 分组1：私募配售信息 - 公司提交发售文件，进行非经纪私募配售，最多发售16,666,667个单位，每个单位0.12美元，预计筹集最多2,000,000.04美元 [1] - 每个单位包含一股普通股和一份认股权证，认股权证可在发行后36个月内以每股0.20美元的价格购买一股普通股 [2] 分组2：资金用途 - 公司计划将融资净收益用于资本支出、库存以及一般公司和营运资金用途 [3] 分组3：交易时间与条件 - 融资预计在2025年5月9日或之前完成，可能分多批完成，需获得TSX Venture Exchange等必要批准 [4] - 公司可能向合格中介支付最多为融资总收益8%的现金费用 [4] 分组4：发售对象与文件 - 依据相关规定，单位将向加拿大居民发售，且此类证券无持有期限制 [6] - 可在www.sedarplus.ca和公司网站www.volatusaerospace.com获取发售文件，投资者投资前应阅读 [7] 分组5：公司介绍 - 公司是全球智能和货运航空解决方案的领导者，拥有超100年航空领域知识，为多行业提供综合解决方案，致力于提升运营效率、安全性和可持续性 [8]

文章核心观点 - 临床阶段生物技术公司TScan Therapeutics宣布其一篇摘要被即将举行的美国基因与细胞治疗学会第28届年会接受进行海报展示 [1] 海报展示详情 - 标题为“CD45作为异基因造血细胞移植后辅助TCR - T细胞治疗的通用靶点” [2] - 作者包括Kostadin O Petrov等众多人员 [2] - 摘要编号为AMA1180 [2] - 会议日期/时间为5月13日周二下午6:00 - 7:30（中部时间） [2] - 地点在新奥尔良LA的海报厅I2 [2] - 展示结束后展示材料副本将添加到公司网站“出版物”部分 [2] 公司介绍 - 公司是专注于开发T细胞受体（TCR）工程化T细胞（TCR - T）疗法治疗癌症患者的临床阶段生物技术公司 [1][3] - 公司领先的TCR - T疗法候选药物正用于治疗血液系统恶性肿瘤患者，以防止异基因造血细胞移植后复发（ALLOHA™ 1期血液试验） [3] - 公司开发并持续扩展其ImmunoBank，为各种癌症患者提供定制的多重TCR - T疗法（PLEXI - T™ 1期实体瘤试验） [3] - 公司目前正在两个临床项目中招募患者 [3] 联系方式 - 公司投资者关系副总裁Heather Savelle，电话857 - 399 - 9840，邮箱hsavelle@tscan.com [4] - Argot Partners的Maghan Meyers，电话212 - 600 - 1902，邮箱TScan@argotpartners.com [4]

Reflects business philosophy of commercial success through patient accessibilityRecently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder equity WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5- ...

Prolonged duration of response, deep B-cell depletion, and well-tolerated safety profile support the potential of AlloNK® + rituximab for the treatment of B-cell driven diseases in a community setting Additional poster presentation to feature scalability and consistency of AlloNK manufacturing process SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for ...